Daiichi Sankyo lures former Kite exec to head up its R&D

22 February 2021

Japan’s Daiichi Sankyo (TYO: 4568) today announced Ken Takeshita will be named the new global head of Research & Development as of April 1, 2021.

On that date, Dr Junichi Koga will retire from the position, after a successful and industrious career, including more than 12 years at Daiichi Sankyo.

Dr Takeshita joins Daiichi Sankyo from Kite Pharma, a Gilead Sciences (Nasdaq: GILD) subsidiary, where he was senior vice president and global head of development since 2019, and interim head of research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK